Unicycive Therapeutics (UNCY) AI Stock Analysis

• Market Cap: $51.20M
• Dividend Yield: N/A
• Average Volume (3M): 522.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: N/A
• EPS Growth: 88.03%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 12,768,239
• 10 Day Avg. Volume: 326,545
• 30 Day Avg. Volume: 522,521
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.27
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.60
• 1Y Price Target: $51.50
• Price Target Upside: 1111.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 28 Underperform
• Price Target: ―

Unicycive Therapeutics has significant financial challenges, including ongoing net losses and a reliance on debt for financing, which weigh heavily on its stock score. The technical analysis reveals a bearish trend, as the stock is trading below major moving averages. Valuation metrics further dampen the attractiveness of the stock due to negative profitability indicators. Without earnings call insights or recent corporate events to improve prospects, the overall score reflects these financial and technical weaknesses.

Positive Factors

Market Potential

Considering the large market potential, a well-thought-out OLC commercial strategy, and committed funding from accredited investors, UNCY is attractive to a long-term investor.

Patient Outcomes

The P2 study of OLC demonstrated strong patient-reported outcomes, reducing pill burden by 50%, improving adherence, and achieving higher satisfaction compared to prior phosphate binders.

Regulatory Approval

No concerns with the drug’s safety or efficacy, leading to a positive outlook on OLC eventually receiving approval for the treatment of hyperphosphatemia following a delay.

Negative Factors

Manufacturing Issues

The FDA has identified a cGMP compliance-related deficiency with the company’s third-party manufacturing vendor.

Regulatory Delays

Management plans to seek a Type A meeting with the FDA due to issues raised in the CRL, which relate solely to a failed cGMP inspection.

Unicycive Therapeutics Business Overview & Revenue Model

Company Description

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

How the Company Makes Money

Unicycive Therapeutics makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model primarily involves conducting research and development to bring its therapeutic products through clinical trials and eventually to market. Key revenue streams include potential sales from its approved drugs, licensing agreements, and partnerships with other pharmaceutical companies. Unicycive may also receive milestone payments and royalties from collaborations or licensing deals that leverage its proprietary technologies and drug candidates.

Unicycive Therapeutics Financial Statement Overview

Summary

Unicycive Therapeutics faces substantial financial challenges typical of early-stage biotech companies. The absence of revenue growth and consistent net losses present significant hurdles. While there is some improvement in equity, the company's heavy reliance on debt and external financing poses financial risks. Management must focus on operational efficiencies and sustainable revenue generation to improve financial health.

Income Statement

Unicycive Therapeutics has struggled with revenue generation, as evidenced by zero total revenue in the latest year, and has consistently reported negative net income. The company's EBIT and EBITDA margins are negative, indicating ongoing operational challenges. Despite a previous revenue presence, the lack of sustainable growth is concerning.

Balance Sheet

The balance sheet shows significant liabilities compared to equity, with a debt-to-equity ratio that suggests high financial leverage. However, the equity position has improved from negative to positive, indicating some recovery. The equity ratio remains low, highlighting a heavy reliance on debt.

Cash Flow

Free cash flow is negative, reflecting cash consumption for operations, which is a common challenge in early-stage biotech firms. Positive financing cash flow indicates reliance on external funding. The operating cash flow to net income ratio suggests inefficiencies in converting earnings to cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	675.00K	951.00K	0.00	0.00
Gross Profit	0.00	675.00K	944.00K	-1.00K	0.00
EBITDA	-36.23M	-30.18M	-18.05M	-8.98M	0.00
Net Income	-36.73M	-30.54M	-18.06M	-10.63M	-2.51M
Balance Sheet
Total Assets	31.67M	14.19M	2.82M	18.74M	204.00K
Cash, Cash Equivalents and Short-Term Investments	26.14M	9.70M	455.00K	16.58M	0.00
Total Debt	773.00K	811.00K	155.00K	306.00K	2.51M
Total Liabilities	24.24M	18.00M	3.28M	2.26M	2.88M
Stockholders Equity	7.43M	-3.81M	-466.00K	16.48M	-2.67M
Cash Flow
Free Cash Flow	-28.65M	-18.30M	-15.65M	-5.80M	-1.46M
Operating Cash Flow	-28.57M	-18.28M	-15.65M	-5.77M	-1.46M
Investing Cash Flow	-72.00K	-12.00K	-2.00K	-29.00K	0.00
Financing Cash Flow	45.09M	27.54M	-471.00K	22.38M	1.44M

Unicycive Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNCY, the sentiment is Negative. The current price of 4.25 is below the 20-day moving average (MA) of 4.40, below the 50-day MA of 5.46, and below the 200-day MA of 5.89, indicating a bearish trend. The MACD of -0.33 indicates Negative momentum. The RSI at 41.78 is Neutral, neither overbought nor oversold. The STOCH value of 25.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UNCY.

Unicycive Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TCRX	53 Neutral	$91.11M	―	-63.33%	―	-42.94%	―
Sector *	47 Neutral	C$212.69M	-2.68	-24.76%	3.10%	19.76%	0.48%
IMAB	45 Neutral	$307.08M	―	-22.38%	―	-100.00%	72.51%
ADAG	44 Neutral	$89.98M	―	-55.14%	―	-99.43%	-69.40%
SGMT	44 Neutral	$268.40M	―	-34.72%	―	-100.00%	-48.21%
ADVM	44 Neutral	$46.80M	―	-222.28%	―	―	1.80%
UNCY	28 Underperform	$51.20M	―	-2355.27%	―	―	88.03%